Literature DB >> 33449875

Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multi-step binding process.

F Peter Guengerich1, Kevin D McCarty2, Jesse G Chapman2.   

Abstract

Cytochrome P450 (P450, CYP) 3A4 is the enzyme most involved in the metabolism of drugs and can also oxidize numerous steroids. This enzyme is also involved in one-half of pharmacokinetic drug-drug interactions, but details of the exact mechanisms of P450 3A4 inhibition are still unclear in many cases. Ketoconazole, clotrimazole, ritonavir, indinavir, and itraconazole are strong inhibitors; analysis of the kinetics of reversal of inhibition with the model substrate 7-benzoyl (OBz) quinoline showed lag phases in several cases, consistent with multiple structures of P450 3A4 inhibitor complexes. Lags in the onset of inhibition were observed when inhibitors were added to P450 3A4 in 7-OBz quinoline O-debenzylation reactions, and similar patterns were observed for inhibition of testosterone 6β-hydroxylation by ritonavir and indinavir. Upon mixing with inhibitors, P450 3A4 showed rapid binding as judged by a spectral shift with at least partial high-spin iron character, followed by a slower conversion to a low-spin iron-nitrogen complex. The changes were best described by two intermediate complexes, one being a partial high-spin form and the second another intermediate, with half-lives of seconds. The kinetics could be modeled in a system involving initial loose binding of inhibitor, followed by a slow step leading to a tighter complex on a multi-second time scale. Although some more complex possibilities cannot be dismissed, these results describe a system in which conformationally distinct forms of P450 3A4 bind inhibitors rapidly and two distinct P450-inhibitor complexes exist enroute to the final enzyme-inhibitor complex with full inhibitory activity.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytochrome P450; enzyme inhibitor; enzyme kinetics; enzyme mechanism; pre-steady-state kinetics; ultraviolet-visible spectroscopy (UV-Vis spectroscopy)

Year:  2020        PMID: 33449875      PMCID: PMC7948456          DOI: 10.1074/jbc.RA120.016855

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

2.  Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  J Biol Chem       Date:  2007-01-02       Impact factor: 5.157

3.  Drug-related deaths in hospital inpatients: A retrospective cohort study.

Authors:  Eva Montané; Ana Lucía Arellano; Yolanda Sanz; Josep Roca; Magí Farré
Journal:  Br J Clin Pharmacol       Date:  2018-01-11       Impact factor: 4.335

4.  Conformational Response of N-Terminally Truncated Cytochrome P450 3A4 to Ligand Binding in Solution.

Authors:  Shih-Wei Chuo; Shu-Hao Liou; Lee-Ping Wang; R David Britt; Thomas L Poulos; Irina F Sevrioukova; David B Goodin
Journal:  Biochemistry       Date:  2019-09-06       Impact factor: 3.162

5.  Structural basis for ligand promiscuity in cytochrome P450 3A4.

Authors:  Marika Ekroos; Tove Sjögren
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

6.  Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.

Authors:  F P Guengerich
Journal:  Chem Res Toxicol       Date:  1990 Jul-Aug       Impact factor: 3.739

7.  Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

8.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

Authors:  Y F Ueng; T Kuwabara; Y J Chun; F P Guengerich
Journal:  Biochemistry       Date:  1997-01-14       Impact factor: 3.162

9.  Reductive-oxygenation mechanism of metabolism of carbon tetrachloride to phosgene by cytochrome P-450.

Authors:  L R Pohl; R D Schulick; R J Highet; J W George
Journal:  Mol Pharmacol       Date:  1984-03       Impact factor: 4.436

10.  Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity.

Authors:  Stella A Child; F Peter Guengerich
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

View more
  2 in total

1.  In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.

Authors:  Yujie Wu; Aiqing Qiao; Shu Lin; Lijia Chen
Journal:  BMC Complement Med Ther       Date:  2022-02-18

Review 2.  Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.

Authors:  F Peter Guengerich
Journal:  Biomol Ther (Seoul)       Date:  2022-01-01       Impact factor: 4.634

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.